title: Review of adverse reactions to injections of Chinese materia medica.
abstract: Using Chinese Materia Medica (CM) as injections is an innovation that is proving effective in extensive clinical use in Mainland China. However, recent reports have focused on adverse reactions, ignoring the considerable successes of these preparations. In order to achieve balance in the media and in the minds of the public, we suggest the first step is to clarify the concepts of and differences between adverse drug reactions (ADR) and adverse events (AE) for all concerned-the public, medical practitioners, government officials, and lawmakers. Second, the State Food and Drug Administration should raise the requirements for Chinese Materia Medica Injection (CMI) registration and license approval and emphasize the importance of evidence-based CMI development and evidence-based CMI license approval. Thirdly, drug companies and institutions should reinforce basic research about the quality control of herbs and CMI-drug interactions. Fourth, the Government should clarify the legal responsibilities for CMI approval agencies, CMI developers, medical doctors, and patients. Fifth, the medical association and Government should enhance training for health care professionals concerning the usage of CMIs. And finally sixth, State Food and Drug Administration should monitor the content and quality of the directions for use of CMI.
authors.affiliation: Hong Kong Baptist University, Hong Kong, China Tianjin University of Traditional Chinese Medicine, Tianjin, China. bzxiang@hkbu.edu.hk
authors.forename: Zhaoxiang
authors.initials: Z
authors.lastname: Bian
authors.forename: Hongcai
authors.initials: H
authors.lastname: Shang
authors.forename: Chungwah
authors.initials: C
authors.lastname: Cheng
authors.forename: Taixiang
authors.initials: T
authors.lastname: Wu
authors.forename: Youping
authors.initials: Y
authors.lastname: Li
authors.forename: Boli
authors.initials: B
authors.lastname: Zhang
mesh_terms: D002681:China; D004347:Drug Interactions; D006801:Humans; D008419:Materia Medica / Q000008:administration & dosage / Q000009:adverse effects*; D008516:Medicine, Chinese Traditional / Q000009:adverse effects*; D011786:Quality Control
chemical_list: D008419:Materia Medica